Cormedix SEC Filings

CorMedix, Inc. (CRMD) filed a shelf registration on Form S-3ASR to allow selling securityholders to offer up to 6,323,833 shares of common stock. The company will not receive proceeds from these sales. Principal selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with detailed allocations showing 2,551,042 and 772,791 shares issued under the Merger Agreement, plus potential 2,302,500 and 697,500 milestone shares issuable under a contingent purchase agreement (CPA) through June 30, 2029. Shares for milestones will be valued using the five-day VWAP before each milestone date. The prospectus references risk factors and incorporates the companyForm 10-K for fiscal 2024 filed March 25, 2025. A listed legal fees line item shows $140,000.

CorMedix Inc. (CRMD) has a shelf prospectus for resale of up to 6,323,833 shares of common stock by selling securityholders; the company will not receive proceeds from those sales. The shares include amounts issued under a Merger Agreement and potential milestone shares issuable under a Collaboration and Purchase Agreement (CPA) through June 30, 2029, with milestone share valuation tied to a five-day VWAP on the Nasdaq prior to each milestone. Named selling holders include Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P., with specified allocations of Merger and potential milestone shares. The Nasdaq Global Market ticker is CRMD. The prospectus refers investors to the Risk Factors section and incorporated reports for further details.

CorMedix Inc. director Gregory Scott Duncan reported insider transactions on 09/16/2025. The filing shows an acquisition of 13,333 shares of common stock at $8.32 per share, bringing his total common stock beneficially owned to 38,333 shares. The report also lists a derivative transaction showing 13,333 stock options with an $8.32 exercise price, exercisable beginning 01/10/2031, and 6,667 derivative shares beneficially owned following the transaction. The form notes these options were granted 01/11/2021 and vest monthly with full vesting after one year, subject to continued board service.

Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.

CorMedix Inc. is soliciting votes at a virtual special meeting to approve three proposals: removal of an exchange cap, an amendment to its 2022 Stock Incentive Plan to increase authorized shares from 8,160,000 to 12,472,000, and an adjournment proposal. The amendment would make the additional shares available for a variety of equity awards including incentive stock options, SARs, restricted stock and RSUs to attract and retain employees, consultants and directors. The proxy discloses potential contingent consideration tied to a prior transaction including up to $25,000,000 in milestone payments payable in cash, stock or warrants and references Merger Warrants and Notes. The company reported the Nasdaq closing price of its common stock as $12.75 on September 8, 2025. The materials explain voting mechanics, broker non-vote treatment, beneficial ownership disclosure for certain holders and deadlines for 2026 stockholder proposals.

CorMedix Inc. insider Beth Zelnick Kaufman reported multiple transactions on 09/09/2025. She acquired 50,000 shares by exercising options at an exercise price of $3.30 (options originally granted 12/12/2023, vesting over four years). On the same date she disposed of 49,600 shares at a weighted average price of $13.41 and 400 shares at $12.82. Following these trades her beneficial ownership is reported as 180,418 shares.

Elizabeth Hurlburt, Chief Operating Officer of CorMedix Inc. (CRMD), reported option exercises and subsequent open-market sales in September 2025. On 09/09/2025 she exercised 12,876 stock options at an exercise price of $1.45 and sold 12,876 shares at a weighted average price of $13.51. On 09/11/2025 she exercised 41,121 options at $1.45 and sold 41,121 shares at a weighted average price of $13.08. Following these transactions her beneficial ownership is reported as 176,990 shares. The exercised options were originally granted 03/19/2018 with scheduled vesting and milestone-based vesting for remaining amounts.